Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
J Neurooncol. 2018 Sep;139(2):399-409. doi: 10.1007/s11060-018-2877-6. Epub 2018 Apr 20.
To report the potential value of pre-operative F-FDOPA PET and anatomic MRI in diagnosis and prognosis of glioma patients.
Forty-five patients with a pathological diagnosis of glioma with pre-operative F-FDOPA PET and anatomic MRI were retrospectively examined. The volume of contrast enhancement and T2 hyperintensity on MRI images along with the ratio of maximum F-FDOPA SUV in tumor to normal tissue (T/N SUV) were measured and used to predict tumor grade, molecular status, and overall survival (OS).
A significant correlation was observed between WHO grade and: the volume of contrast enhancement (r = 0.67), volume of T2 hyperintensity (r = 0.42), and F-FDOPA uptake (r = 0.60) (P < 0.01 for each correlation). The volume of contrast enhancement and F-FDOPA T/N SUV were significantly higher in glioblastoma (WHO IV) compared with lower grade gliomas (WHO I-III), as well as for high-grade gliomas (WHO III-IV) compared with low-grade gliomas (WHO I-II). Receiver-operator characteristic (ROC) analyses confirmed the volume of contrast enhancement and F-FDOPA T/N SUV could each differentiate patient groups. No significant differences in F-FDOPA uptake were observed by IDH or MGMT status. Multivariable Cox regression suggested age (HR 1.16, P = 0.0001) and continuous measures of F-FDOPA PET T/N SUV (HR 4.43, P = 0.016) were significant prognostic factors for OS in WHO I-IV gliomas.
Current findings suggest a potential role for the use of pre-operative F-FDOPA PET in suspected glioma. Increased F-FDOPA uptake may not only predict higher glioma grade, but also worse OS.
报告术前 F-FDOPA PET 和解剖 MRI 在诊断和预测胶质瘤患者预后中的潜在价值。
回顾性检查了 45 例术前 F-FDOPA PET 和解剖 MRI 检查的病理诊断为胶质瘤的患者。测量 MRI 图像上的对比增强和 T2 高信号体积以及肿瘤与正常组织之间的最大 F-FDOPA SUV 比值(T/N SUV),用于预测肿瘤分级、分子状态和总生存期(OS)。
发现 WHO 分级与:对比增强体积(r=0.67)、T2 高信号体积(r=0.42)和 F-FDOPA 摄取(r=0.60)之间存在显著相关性(每项相关性 P<0.01)。与低级别胶质瘤(WHO I-III)相比,胶质母细胞瘤(WHO IV)的对比增强体积和 F-FDOPA T/N SUV 明显更高,与低级别胶质瘤(WHO I-II)相比,高级别胶质瘤(WHO III-IV)的对比增强体积和 F-FDOPA T/N SUV 也明显更高。受试者工作特征(ROC)分析证实,对比增强体积和 F-FDOPA T/N SUV 均能区分患者群体。IDH 或 MGMT 状态对 F-FDOPA 摄取无显著差异。多变量 Cox 回归表明,年龄(HR 1.16,P=0.0001)和 F-FDOPA PET T/N SUV 的连续测量(HR 4.43,P=0.016)是 WHO I-IV 级胶质瘤 OS 的显著预后因素。
目前的研究结果表明,术前 F-FDOPA PET 在疑似胶质瘤中的应用具有潜在作用。F-FDOPA 摄取增加不仅可以预测更高的胶质瘤分级,而且可能预示着更差的 OS。